Show Summary Details
Page of

Cancer of unknown primary site 

Cancer of unknown primary site
Chapter:
Cancer of unknown primary site
Author(s):

Nicholas Pavlidis

and George Pentheroudakis

DOI:
10.1093/med/9780199656103.003.0059_update_002

Updates

No data on the use of targeted therapy (TKIs, mTOR, monoclonal antibodies, or check point inhibitors) are yet available.

GEFCAPI 04 prospective randomized trial between molecularly-guided therapy versus empirical therapy is urgently awaited.

Gene profiling diagnosis should not be in daily practice use.

Updated on 29 March 2019. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 August 2019

This chapter covers cancer of unknown primary site (CUP), and includes information on epidemiology, molecular biology, pathology, and multidisciplinary management of clinicopathological subsets. Previously, these tumours were diagnosed and treated based on clinical presentation, light microscopy and clinical intuition. Today, the majority of cancers of unknown primary site are becoming less unknown, more accurately classified, and appropriately treated by the use of multiplex or genome-wide expression profiling platforms. These techniques allow for precise and correct knowledge of the true tumour origin, leading to more rational and effective treatment. However, there also may be genetic signatures that are primary-independent, pro-metastatic, and possibly CUP-specific.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.